This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
REFERENCES
Arndt M, Lendeckel U, Spiess A, Faust J, Neubert K, Reinhold D, and Ansorge S, 2000, Dipeptidyl peptidase IV (DP IV/CD26) mRNA expression in PWM-stimulated T-cells is suppressed by specific DP IV inhibition, an effect mediated by TGF-á1. Biochem. Biophys. Res. Comm. 274: 410–414.
Ansorge S, Schön E, and Kunz D, 1991, Membrane-bound peptidases of lymphocytes: Functional implications. Biomed. Biochem. Acta 50: 799–807.
Bomprezzi R, Ringner M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, and Trent JM, 2003, Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 12: 2191–2199.
Cavani A, Nasorri F, Prezzi C, Sebastiani S, Albanesi C, and Girolomoni G, 2000, Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickelspecific Th1 immune responses. J. Invest. Dermatol. 114:295–302.
Constantinescu CS, Kamoun M, Dotti M, Farber RE, Galetta SL, and Rostami A, 1995, A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis. J. Neurol. Sci. 130: 178–182.
Dang NH, Torimoto Y, Deusch K, Schlossman SF, and Morimoto C, 1990, Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J. Immunol. 144: 4092–4100.
De Meester I, Korom S, Van Damme J, and Scharpe’ S, 1999, CD26, let it cut or cut it down. Immunol. Today 20: 367–375.
Fleischer B, 1994, CD26: a surface protease involved in T-cell activation. Immunol. Today 15: 180–184.
Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, and Weiner HL, 1985, In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N. Engl. J. Med. 312: 1405–1411.
Hanski C, Huhle T, and Reutter W, 1985, Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol. Chem. Hoppe-Seyler 366: 1169–1176.
Hoffmann T, Reinhold D, K,hne T, Faust J, Neubert K, Frank R, and Ansorge S, 1995, Inhibition of dipeptidyl peptidase IV by anti-DP IV antibodies and non-substrate X-XPro-oligopeptides ascertained by capillary electrophoresis. J. Chromat. 716: 355–362.
Hopsu-Havu KV, and Glenner GG, 1966, A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 7: 197–201.
Ishii T, Ohnuma K, Murakami A, Takasawa N, Kobayashi S, Dang NH, Schlossman SF, and Morimoto C, 2001, CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc. Natl. Acad. Sci. USA 98: 12138–12143.
Iwata S, Yamaguchi N, Munakata Y, Ikushima H, Lee JF, Hosono O, Schlossman SF, and Morimoto C, 1999, CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int. Immunol. 11: 417–426.
James MJ, Belaramani L, Prodromidou K, Datta A, Nourshargh S, Lombardi G, Dyson J, Scott D, Simpson E, Cardozo L, Warrens A, Szydlo RM, Lechler RI, and Marelli-Berg FM, 2003, Anergic T cells exert antigen-independent inhibition of cell-cell interactions via chemokine metabolism.Blood 102: 2173–2179.
Jensen J, Langkilde AR, Fenst C, Nicolaisen MS, Roed HG, Christiansen M, and Sellebjerg F, 2004, CD4 T cell activation and disease activity at onset of multiple sclerosis. J. Neuroimmunol. 149: 202–209.
Kähne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, and Reinhold D, 1999, Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth. Int. J. Mol. Med. 4: 3–15.
Kameoka J, Tanaka T, Nojima Y, Schlossman SF, and Morimoto C, 1993, Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261: 466–469.
Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, and Weiner HL, 2000, Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch. Neurol. 57: 1183–1189.
Korom S, De Meester I, Onodera K, Stadlbauer THW, Borloo M, Lambeir AM, and Kupiec-Weglinski JW, 1997a, The efffects of CD26/DPP IV-targeted therapy on acute allograft rejection. Transplant. Proc. 29: 1274–1275.
Korom S, De Meester I, Stadlbauer THW, Chandraker A, Schaub M, Sayagh MH, Belyaev A, Haemers H, Scharpe’ S, and Kupiec-Weglinski JW, 1997b, Inhibition of CD26/ Dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 63: 1495–1500.
Korom S, De Meester I, Coito AJ, Graser E, Pratschke J, König S, Grimm H, Volk HD, Scharpe’ S, and Kupiec-Weglinski JW, 1999, CD26/DPP IV-mediated modulation of acute rejection. Transplant. Proc. 31: 873.
Kuramoto T, Kitada K, Inui T, Sasaki Y, Ito K, Hase T, Kawagachi S, Ogawa Y, Nakao K, Barsh GS, Nagao M, Ushijima T, and Serikawo T, 2001, Attractin/mahogany/zitter plays a critical role in myelination of the central nervous system. Proc. Natl. Acad. Sci. USA 98: 559–564.
Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, Scharpe S, Van Damme J, and De Meester I, 2001, Kinetic investigation of chemokine truncation by CD26/Dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. 276: 29839–29845.
Lojda Z, 1977, Studies on glycyl-proline naphthylamidase. I. Lymphocytes. Histochemistry 54: 299–309.
Pauly RP, Rosche F, Wermann M, McIntosh CHS, Pederson RA, and Demuth HU, 1996, Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization time of flight mass spectrometry-A novel kinetic approach. J. Biol. Chem. 271: 23222–23229.
Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir AM, Neyts J, Liekens S, Maudal PC, Billiau A, and van Damme J, 2001, Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 13: 3554–3561.
Reinhold D, Bank, U, Bühling F, Lendeckel U, Ulmer AJ, Flad H, and Ansorge S, 1994, Transforming growth factor-β1 (TGF-β1) inhibits DNA synthesis of PWM stimulated PBMC via suppression of IL-2 and IL-6 production. Cytokines 6: 382–388.
Reinhold D, Bank, U, Bühling F., Lendeckel U, and Ansorge S, 1995, Transforming Growth Factor beta1 inhibits Interleukin-10 mRNA expression and production in pokeweed mitogen-stimulated peripheral blood mononuclear cells and T cells. J. Interferon Cytokine Res. 15: 685–690.
Reinhold D, Bank, U, Bühling F, Lendeckel U, Faust J, Neubert K, and Ansorge S, 1997a, Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth in PWM-stimulated PBMC and T cells.Immunology 91: 354–360.
Reinhold D, Bank, U, Bühling F, Täger M, Born I, Faust J, Neubert K, and Ansorge S, 1997b, Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-á1 (TGF-á1) in stimulated mouse splenocytes and thymocytes. Immunol. Lett. 58: 29–35.
Reinhold D, Hemmer B, Gran B, Borth I, Faust J, Neubert K, McFarland HF, Martin R, and Ansorge S, 1998, Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones. J. Neuroimmunol. 87: 203–209.
Rogge L, Bianchi E, Biffi M, Bono E, Chang SY, Alexander H, Santini C, Ferrari G, Sinigaglia L, Seiler M, Neeb M, Mous J, Sinigaglia F, and Certa U, 2000, Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat. Genet. 25: 96–101.
Schön E, Mansfeld HW, Demuth HU, Barm A, and Ansorge S, 1985. The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed. Biochem. Acta 44: K9–K15.
Sedo A, Malik R, 2001, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Bioch. Biophys. Acta 1550: 107–116.
Sellebjerg F, Madsen HO, Jensen CV, Jensen J, and Garred P, 2000a, CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102: 98–106.
Sellebjerg F, Christiansen M, Jensen J, and Frederiksen JL, 2000b, Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur. J. Neurol. 7:281–289.
Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, and Brocke S, 2000, Dipeptidyl peptidase IV in inflammatory CNS disease. Adv. Exp. Med. Biol. 477: 145–153.
Sellebjerg F, Christiansen M, Jensen J, and Frederiksen JL, 2000b, Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur. J. Neurol. 7:281–289.
Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, and Brocke S, 2000, Dipeptidyl peptidase IV in inflammatory CNS disease. Adv. Exp. Med. Biol. 477: 145–153.
Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, and Brocke S, 2001, Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and upregulates TGF-á1 secretion in vivo.J. Immunol. 166: 2041–2048.
Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, and Sugita T, 1997, Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. 19: 15–24.
Tanaka S, Murakami T, Nonaka N, Ohnuki T, Yamada M, and Sugita T, 1998, Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacol. 40: 21–26.
Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, and Morimoto C, 1991, Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J. Immunol. 147: 2514–2517.
Vivier I, Marguet D, Naquet P, Bonicel J, Black D, Xiao-Yan LC, Bernard AM, Gorvel JP, and Pierres M, 1991, Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). J. Immunol. 147: 447–454.
Wrenger S, Hoffmann T, Faust J, Mrestani-Klaus C, Brandt W, Neubert K, Kraft M, Olek S, Frank R, Ansorge S, and Reinhold D, 1997, The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth.J. Biol. Chem. 272: 30283–30288.
Wrenger S, Faust J, Mrestani-Klaus C, Fengler A, Stöckel-Maschek A, Lorey S, Kähne T, Brandt W, Neubert K, Ansorge S, and Reinhold D, 2000, Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor. J. Biol. Chem. 275: 22180–22186.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science + Business Media, Inc. Dordrecht
About this chapter
Cite this chapter
Brocke, S. et al. (2005). Dipeptidyl Peptidase IV Regulates T Cell Function in CNS Inflammation. In: Lendeckel, U., Hooper, N.M. (eds) Proteases In The Brain. Proteases In Biology and Disease, vol 3. Springer, Boston, MA. https://doi.org/10.1007/0-387-23101-3_6
Download citation
DOI: https://doi.org/10.1007/0-387-23101-3_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-23100-6
Online ISBN: 978-0-387-23101-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)